Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab after complete resection of high-risk stage III melanoma; results posted for MK-3475-054/1325-MG/KEYNOTE-054 comparing ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-01-04